(marketscreener.com) – Encouraging data from ongoing Phase 1 study of SGN-B6A illustrate commitment to pioneering novel first-in-class antibody-drug conjugates –https//www.marketscreener.com/quote/stock/SEAGEN-INC-10808/news/Seagen-to-Highlight-New-Research-from-its-Diverse-Pipeline-of-Targeted-Cancer-Therapy-Candidates-at-42271646/?utm_medium=RSS&utm_content=20221110

(marketscreener.com) Nes-Ziona, Israel, Nov. 10, 2022 -- Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, today announced a poster presentation at the 37th Annual Meeting of the Society For Immunotherapy Of Cancer, which is taking place both virtually and in-person from November 8, 2022 through November 12, 2022 in...https//www.marketscreener.com/quote/stock/ENLIVEX-THERAPEUTICS-LTD-56422776/news/Enlivex-to-Present-at-the-37th-Annual-Meeting-of-the-Society-For-Immunotherapy-Of-Cancer-42270355/?utm_medium=RSS&utm_content=20221110

(marketscreener.com) Nes-Ziona, Israel, Oct. 03, 2022 -- Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the 4th Macrophage-directed Therapies Summit, which is taking place in Boston, Massachusetts from October 4-6, 2022. Enlivex’s...https//www.marketscreener.com/quote/stock/ENLIVEX-THERAPEUTICS-LTD-56422776/news/Enlivex-to-Present-at-the-4th-Macrophage-Directed-Therapies-Summit-41914340/?utm_medium=RSS&utm_content=20221003

(marketscreener.com) Clinical data on AgenT-797, allogeneic iNKTs, +/- anti-PD-1 in advanced solid tumorsClinical data of AgenT-797 in viral ARDS and refractory multiple myelomaNew therapeutic candidates 1) MiNK-215, an allo-FAP-CAR-iNKT; 2) MiNK-413, allo-armored-BCMA-CAR-iNKT NEW YORK, Oct. 05, 2022 -- MiNK Therapeutics, Inc., a clinical-stage...https//www.marketscreener.com/quote/stock/MINK-THERAPEUTICS-INC-128249930/news/MiNK-Selected-for-Five-Presentations-at-Society-for-Immunotherapy-of-Cancer-s-SITC-37th-Annual-Mee-41933223/?utm_medium=RSS&utm_content=20221005

(marketscreener.com) KNOXVILLE, TN, Nov. 10, 2022 -- Provectus today announced that data from the Company’s ongoing, multi-cohort, Phase 1b/2 study of the combination therapy of cancer immunotherapy PV-10, an intratumoral formulation of Provectus’ small molecule rose bengal sodium , and immune checkpoint inhibitor KEYTRUDA® for the treatment of...https//www.marketscreener.com/quote/stock/PROVECTUS-BIOPHARMACEUTIC-120787445/news/Provectus-Biopharmaceuticals-Announces-Acceptance-of-Small-Molecule-Cancer-Immunotherapy-PV-10-Stag-42270363/?utm_medium=RSS&utm_content=20221110

(marketscreener.com) Kineta, Inc. , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the first patient has been dosed in a Phase 1/2 clinical study evaluating KVA12123 alone and in combination with the immune checkpoint inhibitor pembrolizumab in patients with...https//www.marketscreener.com/quote/stock/YUMANITY-THERAPEUTICS-117003859/news/Yumanity-Therapeutics-VISTA-blocking-immunotherapy-engineered-to-address-immunosuppression-in-the-43475181/?utm_medium=RSS&utm_content=20230412

(marketscreener.com) WALTHAM, Mass., Oct. 05, 2022 -- TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor engineered T cell therapies for the treatment of patients with cancer, today announced the acceptance of two abstracts at the upcoming Society for Immunotherapy of Cancer 37th Annual...https//www.marketscreener.com/quote/stock/TSCAN-THERAPEUTICS-INC-124803355/news/TScan-Therapeutics-Announces-Upcoming-Poster-Presentations-at-the-37th-Society-for-Immunotherapy-of-41933313/?utm_medium=RSS&utm_content=20221005

A team of researchers at The University of Texas MD Anderson Cancer Center has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy. The preclinical findings suggest this adaptable immune conversion approach has the potential for broad application across many cancer types.

(marketscreener.com) CRB-601 is a potent and selective anti-αvβ8 integrin monoclonal antibody designed to block the activation of latent TGFβ selectively within the tumor microenvironmentCRB-601 significantly inhibits tumor growth as a single agent and enhances the efficacy of anti-PD-1 immunotherapy in checkpoint inhibitor sensitive and...https//www.marketscreener.com/quote/stock/CORBUS-PHARMACEUTICALS-HO-21683508/news/Corbus-Presents-Latest-Preclinical-Data-for-CRB-601-at-the-Society-for-Immunotherapy-of-Cancer-SITC-42271661/?utm_medium=RSS&utm_content=20221110

(marketscreener.com) SAN DIEGO, Oct. 05, 2022 -- Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present clinical and preclinical data for the Company’s induced pluripotent stem cell product platform...https//www.marketscreener.com/quote/stock/FATE-THERAPEUTICS-INC-14297698/news/Fate-Therapeutics-to-Present-Clinical-and-Preclinical-Data-for-iPSC-Product-Platform-at-the-Society-41932857/?utm_medium=RSS&utm_content=20221005

(marketscreener.com) BOSTON, Oct. 05, 2022 -- Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today three poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual...https//www.marketscreener.com/quote/stock/CUE-BIOPHARMA-INC-39051301/news/Cue-Biopharma-Announces-Upcoming-Scientific-Presentations-at-the-Society-for-Immunotherapy-of-Cancer-41932866/?utm_medium=RSS&utm_content=20221005

Greg Swain is just one of about 700 Australians diagnosed with mesothelioma last year. With a breakthrough immunotherapy treatment now available to him, he says the despair brought on by his diagnosis is gone.

(marketscreener.com) -- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 -- ChemoCentryx, Inc., , today announced two upcoming poster presentations for CCX559, the Company’s...https//www.marketscreener.com/quote/stock/CHEMOCENTRYX-INC-9978217/news/ChemoCentryx-Announces-Upcoming-Presentations-for-Orally-Administered-PD-L1-Inhibitor-CCX559-at-th-41933231/?utm_medium=RSS&utm_content=20221005

Treatments intended to desensitise people to peanuts had shown promise in tests, but an analysis suggests they may make dangerous allergic reactions more likely

(marketscreener.com) NKTR-288 upregulated MHC Class I and PD-L1 expression on tumors, enhancing anti-tumor activity when combined with anti-PD-1 or anti-PD-L1 antibodiesSAN FRANCISCO, Nov. 10, 2022 /PRNewswire/ -- Nektar Therapeutics today announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for Immunotherapy of Cancer Annual...https//www.marketscreener.com/quote/stock/NEKTAR-THERAPEUTICS-45013433/news/Nektar-Therapeutics-Presents-Preclinical-Data-from-Novel-PEGylated-Interferon-Gamma-Program-NKTR-28-42271663/?utm_medium=RSS&utm_content=20221110

(marketscreener.com) NEW YORK and VIENNA, Austria, Feb. 13, 2023 -- HOOKIPA Pharma Inc. , a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it has achieved a $10 million non-dilutive milestone payment under its collaboration agreement with Roche to develop HB-700, a novel arenaviral immunotherapy...https//www.marketscreener.com/quote/stock/HOOKIPA-PHARMA-INC-57291650/news/HOOKIPA-Achieves-10-Million-Milestone-Payment-in-Development-of-Immunotherapy-for-KRAS-Mutated-Canc-42972081/?utm_medium=RSS&utm_content=20230213

(marketscreener.com) ImmunityBio, Inc. , a clinical-stage immunotherapy company, announced today that the company will be participating in the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York City, November 29 - December 1, 2022.Details of the presentation can be found below.Piper Sandler Healthcare...https//www.marketscreener.com/quote/stock/IMMUNITYBIO-INC-23160241/news/ImmunityBio-to-Participate-in-34th-Annual-Piper-Sandler-Healthcare-Conference-42345360/?utm_medium=RSS&utm_content=20221117

(marketscreener.com) New preclinical results support self-amplifying vRNA/LNP immunotherapy platform and ongoing IND-enabling studies of ONCR-021ANDOVER, Mass., Oct. 07, 2022 -- Oncorus, Inc. , a viral immunotherapies company focused on stimulating the immune system to transform outcomes for cancer patients, today announced the publication of preclinical data in...https//www.marketscreener.com/quote/stock/ONCORUS-INC-113170571/news/Oncorus-Announces-Publication-in-Nature-Communications-Highlighting-the-Development-of-its-Intraveno-41951897/?utm_medium=RSS&utm_content=20221007

(marketscreener.com) Phio's INTASYL™ compounds demonstrated activity against multiple protein targets including PD-1, BRD4, CTLA-4, TIGIT and CTGF.INTASYL™ compounds demonstrated preclinical activity in both Direct-to-Tumor applications and Adoptive Cell Therapy applications .MARLBOROUGH, Mass., Nov. 10, 2022 /PRNewswire/ -- Phio Pharmaceuticals , a...https//www.marketscreener.com/quote/stock/PHIO-PHARMACEUTICALS-CORP-47281669/news/Phio-Pharmaceuticals-Announces-Study-Results-at-the-37th-Annual-Meeting-of-the-Society-for-Immunothe-42271423/?utm_medium=RSS&utm_content=20221110

(marketscreener.com) Leeds, UK - October 5, 2022 - 4D pharma plc , a pharmaceutical company leading the development of Live Biotherapeutic products , a novel class of drug derived from the microbiome, today announces two poster presentations at the Society for Immunotherapy of Cancer's 37th Annual Meeting , held from November 8-12, 2022. The two...https//www.marketscreener.com/quote/stock/4D-PHARMA-PLC-56171591/news/4D-pharma-Announces-Two-Presentations-at-The-Society-for-Immunotherapy-of-Cancer-Annual-Meeting-S-41933090/?utm_medium=RSS&utm_content=20221005

VANCOUVER, British Columbia — AbCellera (Nasdaq ABCL) today announced a presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022. “T-cell engagers have tremendous potential as precision oncology therapeutics by redirecting cancer-killing T cells to […]

(marketscreener.com) SAN DIEGO, Oct. 05, 2022 -- Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present clinical and preclinical data for the Company’s induced pluripotent stem cell product platform at the...https//www.marketscreener.com/quote/stock/FATE-THERAPEUTICS-INC-14297698/news/Fate-Therapeutics-to-Present-Clinical-and-Preclinical-Data-for-iPSC-Product-Platform-at-the-Society-41932858/?utm_medium=RSS&utm_content=20221005

(marketscreener.com) Leeds, UK - November 10, 2022 - 4D pharma plc , a pharmaceutical company leading the development of Live Biotherapeutic products , a novel class of drug derived from the microbiome, today presented new biomarker data from two ongoing clinical trials of its lead immuno-oncology single strain Live Biotherapeutic, MRx0518, at the at...https//www.marketscreener.com/quote/stock/4D-PHARMA-PLC-56171591/news/4D-pharma-Presents-at-The-Society-for-Immunotherapy-of-Cancer-Annual-Meeting-SITC-2022-42271978/?utm_medium=RSS&utm_content=20221110

(marketscreener.com) Clinical data in nine cancer indications from trial with 264 patients accruedPlenary discussion relating to expansion cohorts represent heavily pretreated patientsAdditional SITC presentations cover 1) botensilimab’s differentiated mechanism; 2) Phase 2 trial of anti-CD73-TGFβ-trap bifunctional antibodyDhan Chand, PhD,...https//www.marketscreener.com/quote/stock/AGENUS-INC-8290/news/Agenus-to-Present-Botensilimab-Data-at-a-Plenary-Session-of-the-Society-for-Immunotherapy-of-Cancer-41932861/?utm_medium=RSS&utm_content=20221005

– Patent covers methods of treating cancer with an IL-2 Superkine and PD1/PDL1 or CTLA-4 checkpoint inhibitor, administered in combination or as a single agent BiSKIT™ TORONTO and HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ MDNA TSX MDNA), a clinical stage immunotherapy company, today announced that the U.S. Patent and […]

(marketscreener.com) New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment OptionsROCHESTER, N.Y., Nov. 10, 2022 -- Vaccinex, Inc. , a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative diseases through the inhibition of semaphorin 4D , and its...https//www.marketscreener.com/quote/stock/VACCINEX-INC-45256990/news/Vaccinex-and-its-Collaborators-Present-Two-Abstracts-Related-to-Pepinemab-Combination-Immunotherapy-42271402/?utm_medium=RSS&utm_content=20221110

(marketscreener.com) Clinical data in nine cancer indications from trial with 264 patients accruedPlenary discussion relating to expansion cohorts represent heavily pretreated patientsAdditional SITC presentations cover 1) botensilimab’s differentiated mechanism; 2) Phase 2 trial of anti-CD73-TGFβ-trap bifunctional antibodyDhan Chand, PhD, Agenus’...https//www.marketscreener.com/quote/stock/AGENUS-INC-8290/news/Agenus-to-Present-Botensilimab-Data-at-a-Plenary-Session-of-the-Society-for-Immunotherapy-of-Cancer-41932863/?utm_medium=RSS&utm_content=20221005

(marketscreener.com) 4D pharma Announces Two Presentations at The Society for Immunotherapy of Cancer Annual Meeting Leeds, UK - October 5, 2022 - 4D pharma plc , a pharmaceutical company leading the development of Live Biotherapeutic products , a novel class of drug derived from the microbiome, today announces two poster presentations at the...https//www.marketscreener.com/quote/stock/4D-PHARMA-PLC-56171591/news/4D-pharma-Announces-Two-Presentations-at-The-Society-for-Immunotherapy-of-Cancer-Annual-Meeting-S-41952804/?utm_medium=RSS&utm_content=20221007

(marketscreener.com) Phio's INTASYL™ compounds demonstrated activity against multiple protein targets including PD-1, BRD4, CTLA-4, TIGIT and CTGF.INTASYL™ compounds demonstrated preclinical activity in both Direct-to-Tumor applications and Adoptive Cell Therapy applications .MARLBOROUGH, Mass., Nov. 10, 2022 /PRNewswire/ -- Phio Pharmaceuticals , a...https//www.marketscreener.com/quote/stock/PHIO-PHARMACEUTICALS-CORP-47281669/news/Phio-Pharmaceuticals-Announces-Study-Results-at-the-37th-Annual-Meeting-of-the-Society-for-Immunothe-42271423/?utm_medium=RSS&utm_content=20221110

According to the National Cancer Institute, T cells are white blood cells apart of the immune system that “develop from stem cells in the bone marrow and can protect the body from infection and may help fight cancer.” But, while battling cancer, many patients’ T cells can become so exhausted that they are no longer […]

(marketscreener.com) Activating Antigen Carriers Shown Preclinically to Activate CD8 T Cells, Increase Their Tumor Infiltration and Drive Tumor KillingDemonstrated Improved Efficacy of AAC Therapy Through Combination with Chemotherapy Agenthttps//www.marketscreener.com/quote/stock/SQZ-BIOTECHNOLOGIES-COMPA-114383843/news/SQZ-Biotechnologies-Publishes-Preclinical-Research-Demonstrating-SQZ-AAC-Platform-s-Potential-as-an-41913415/?utm_medium=RSS&utm_content=20221003

(marketscreener.com) Nes-Ziona, Israel, Nov. 10, 2022 -- Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, today announced a poster presentation at the 37th Annual Meeting of the Society For Immunotherapy Of Cancer, which is taking place both virtually and in-person from November 8, 2022 through November 12, 2022 in...https//www.marketscreener.com/quote/stock/ENLIVEX-THERAPEUTICS-LTD-56422776/news/Enlivex-to-Present-at-the-37th-Annual-Meeting-of-the-Society-For-Immunotherapy-Of-Cancer-42270352/?utm_medium=RSS&utm_content=20221110

(marketscreener.com) REHOVOT, Israel and BETHESDA, MD, Nov. 8, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. , a global leader in the development of cancer related medicine, announced today that it has acquired a controlling interest in TaGeza Biopharmaceuticals Ltd. The TaGeza research team remains committed to the company, and co-founder Prof....https//www.marketscreener.com/quote/stock/CNBX-PHARMACEUTICALS-INC-120793400/news/CNBX-to-Enter-the-Cancer-Immunotherapy-Market-After-Acquiring-a-Controlling-Interest-in-TaGeza-Bioph-42242187/?utm_medium=RSS&utm_content=20221108

(marketscreener.com) SAN CARLOS, Calif., Oct. 05, 2022 -- Iovance Biotherapeutics, Inc. , a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced oral and poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte cell therapies at the Society for Immunotherapy of...https//www.marketscreener.com/quote/stock/IOVANCE-BIOTHERAPEUTICS-36879287/news/Iovance-Biotherapeutics-to-Present-Clinical-Data-for-Lifileucel-Tumor-Infiltrating-Lymphocyte-TIL-41933007/?utm_medium=RSS&utm_content=20221005

(marketscreener.com) SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 -- ALX Oncology Holdings Inc., , a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the acceptance of two Trials in Progress abstracts related to ASPEN-03 and ASPEN-04, the Company’s Phase 2 head and neck cancer studies in...https//www.marketscreener.com/quote/stock/ALX-ONCOLOGY-HOLDINGS-INC-109818466/news/ALX-Oncology-Announces-Trials-in-Progress-Abstracts-Accepted-for-Poster-Presentation-at-the-Society-41932938/?utm_medium=RSS&utm_content=20221005

Experts from Fred Hutchinson Cancer Center will present their latest findings on targets in RIT1-driven cancers, ROR1 CAR T-cell immunotherapy, interplay of the microbiome and genetics in colorectal cancer and more at the annual meeting of the American Association for Cancer Research, to be held April 14-19 in Orlando, Florida.

Cancer treatments like immunotherapy can cause serious side effects, writes Sanofi CEO Paul Hudson.

(marketscreener.com) Poster presentations will highlight Zai’s key internal pipeline programs, ZL-1211 for gastric cancer and ZL-1218 for solid tumorsSHANGHAI and CAMBRIDGE, Mass., Nov. 08, 2022 -- Zai Lab Limited , a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will present new data from its internal immuno-oncology...https//www.marketscreener.com/quote/stock/ZAI-LAB-LIMITED-37797983/news/Zai-Lab-to-Present-New-Oncology-Research-at-2022-Society-for-Immunotherapy-of-Cancer-Annual-Meeting-42241822/?utm_medium=RSS&utm_content=20221108

(marketscreener.com) MARLBOROUGH, Mass., Oct. 6, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. , a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi therapeutic platform, today announced it is scheduled to provide an update on its programs at the 37th Annual Meeting of the Society for...https//www.marketscreener.com/quote/stock/PHIO-PHARMACEUTICALS-CORP-47281669/news/Phio-Pharmaceuticals-Announces-Upcoming-Presentations-at-the-37th-Annual-Meeting-of-the-Society-for-41941549/?utm_medium=RSS&utm_content=20221006

(marketscreener.com) WALTHAM, Mass., Oct. 05, 2022 -- TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor engineered T cell therapies for the treatment of patients with cancer, today announced the acceptance of two abstracts at the upcoming Society for Immunotherapy of Cancer 37th Annual Meeting,...https//www.marketscreener.com/quote/stock/TSCAN-THERAPEUTICS-INC-124803355/news/TScan-Therapeutics-Announces-Upcoming-Poster-Presentations-at-the-37th-Society-for-Immunotherapy-of-41933311/?utm_medium=RSS&utm_content=20221005

(marketscreener.com) SAN DIEGO, Oct. 5, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. , a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it will present a Trial in Progress poster at the upcoming Society for Immunotherapy...https//www.marketscreener.com/quote/stock/POSEIDA-THERAPEUTICS-INC-109519711/news/Poseida-Therapeutics-to-Present-Trial-in-Progress-Poster-for-Phase-1-P-MUC1C-ALLO1-Study-at-the-Soci-41933074/?utm_medium=RSS&utm_content=20221005

Breakthrough solution aims to solve cell transplant rejection issues, paving the way for progress in cellular transplantation and immunotherapy. Researchers at UCSF have come up with a new method that could save lives by stopping antibodies from making the immune system reject engineered therapeutic and transplant cells. Rejection caused by antibodies, as opposed to the […]The post Revolutionary New Method Offers Hope For Successful Cell Transplants appeared first on Revyuh.

(marketscreener.com) – Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells –– AK007 potently blocks all known ligand interaction with Siglec-10, including the “don’t eat me” signal CD24 –– Monotherapy treatment with a Siglec-10 antagonist antibody polarized...https//www.marketscreener.com/quote/stock/ALLAKOS-INC-44979204/news/Allakos-Presents-Preclinical-Data-on-AK007-a-Siglec-10-Antagonist-Antibody-at-the-Society-for-Immu-42271595/?utm_medium=RSS&utm_content=20221110

(marketscreener.com) Adicet to Host R&D Webcast Event on Thursday, November 10, 2022 at 900am ESThttps//www.marketscreener.com/quote/stock/ADICET-BIO-INC-40332178/news/Adicet-Bio-to-Present-Preclinical-Data-from-Allogeneic-Gamma-Delta-T-Cell-Pipeline-Programs-at-The-S-41933004/?utm_medium=RSS&utm_content=20221005

(marketscreener.com) Delivering the Potential of Immunotherapy Corporate Overview J a n u a r y 2 0 2 3 NON-CONFIDENTIAL Legal Disclaimer This presentation and the...https//www.marketscreener.com/quote/stock/ATRECA-INC-59968119/news/Atreca-Corporate-Presentation-January-2023-42692861/?utm_medium=RSS&utm_content=20230109

(marketscreener.com) Data confirms the ability of the VeriStrat® test to predict outcomes in patients with Non-small Cell Lung Cancer treated with immunotherapy regimenshttps//www.marketscreener.com/quote/stock/BIODESIX-INC-114282624/news/Biodesix-Presents-New-Data-from-the-INSIGHT-Study-at-the-2022-Society-for-Immunotherapy-of-Cancer-S-42271777/?utm_medium=RSS&utm_content=20221110

(marketscreener.com) CAMBRIDGE, Mass., Oct. 05, 2022 -- Immuneering Corporation , a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced it will present data on its second program IMM-6-415 in a poster presentation at the 37th Annual Meeting of...https//www.marketscreener.com/quote/stock/IMMUNEERING-CORPORATION-125277856/news/Immuneering-To-Present-Poster-on-IMM-6-415-at-the-37th-Annual-Meeting-of-the-Society-for-Immunothera-41933008/?utm_medium=RSS&utm_content=20221005

(marketscreener.com) 09 January 2023 Aptevo Therapeutics Clinical stage immunotherapy company developing cancer therapeutics NASDAQ APVO Forward-Looking Statements Safe Harbor...https//www.marketscreener.com/quote/stock/APTEVO-THERAPEUTICS-INC-29774500/news/Aptevo-Therapeutics-09-January-Investor-Presentation-42692678/?utm_medium=RSS&utm_content=20230109

(marketscreener.com) BELTSVILLE, Md., Oct. 05, 2022 -- NextCure, Inc. , a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced two presentations at the Society for Immunotherapy of Cancer annual meeting, to be held in Boston in...https//www.marketscreener.com/quote/stock/NEXTCURE-INC-57878446/news/NextCure-to-Give-Two-Presentations-at-Society-for-Immunotherapy-of-Cancer-Annual-Meeting-41933113/?utm_medium=RSS&utm_content=20221005

(marketscreener.com) SAN FRANCISCO, Nov. 8, 2022 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Kiromic Biopharma, Inc. relating to possible false and misleading statements to investors concerning commercial prospects for the company's immunotherapy medications. Kiromic is a target...https//www.marketscreener.com/quote/stock/KIROMIC-BIOPHARMA-INC-113902312/news/SHAREHOLDER-ALERT-Kiromic-Biopharma-Inc-KRBP-Officers-and-Directors-Under-Investigation-for-Pos-42242557/?utm_medium=RSS&utm_content=20221108